Isivivinyo Sesizukulwane Sesine Phakathi Kwezinketho Ezikhethiwe ZamaCDC
Ngesikhathi i-US Food and Drug Administration ivuma ukuthi i-Alere Determine i-Alere Determine HIV-1/2 Ag / Ab Combo test ngomhla ka-Agasti 9, 2013, yamukelwe emhlabeni wonke ngabahlinzeki bezempilo kanye nabenzi bomgomo ngokufanayo. Kwakungekho okwakungakaze kube khona amathuluzi okunakekelwa okutholakala ukuhlola i-HIV-1 noma i-HIV-2, noma leyo engayithola ngokweqile ama-antigen noma i-antibodies.
Ngaphandle kokulula kokusebenza konke okukodwa, i-Alere Determine Combo ikhanda namahlombe ngaphezulu kokuhlolwa kwesizukulwane esidlule, ukunikeza amazinga aphezulu okuzwela, ukucaca kanye nesivinini.
Lokhu kuvivinywa ukuthi yilolu suku phakathi kwezivivinyo ezimbili (eceleni kwe-Abbott ARCHITECT HIV Ag / Ab Combo) ekhuthazwa yiCenter for Disease Control and Prevention njengoba izinketho ezithandwayo zokuthola i-HIV e-US
Nazi amaqiniso angu-5 okufanele uwazi mayelana ne-Alere Determine Combo:
1. I-Determine Combo ayiyona i-over-the-counter yokuhlola i-HIV.
Ngokungafani ne-OraQuick In-Home Oral Test Test, i-Determine Combo iyi-test elula-yegazi ehlolwayo kuphela ehlinzekwa kuphela ezindaweni zokuhlola ezifanelekayo.Noma i-OraQuick inganikeza ukuhlolwa kwekhaya okuyimfihlo kungakapheli imizuzu engama-20, okwamanje kunamanga isilinganiso esibi se-15% (noma cishe ukuhlolwa okungu-7 kokubili).
Ngokuphambene, ukufundwa kwamanga okungalungile ne-Determine Combo kubhekwa kungavamile ngokuzwela kwamaphesenti angu-100.
2. Ukuhlolwa kwama-antigens we-HIV kuvame ukushesha kunokuba kuhlolwe amasosha omzimba.
Ama-antigens yizinto ezingaphandle ezenza umzimba ukwazi ukukhiqiza ama-antibodies omzimba.
Ngakho-ke, njengomthetho, ukuhlolwa okusheshayo kwama-antigens e-HIV kunikeza imiphumela esheshayo kunokuhlolwa kwe-antibody. Endabeni ye-Determine Combo, sikhuluma imiphumela ezinsukwini ezingu-12 kuya kwezingu-26 ezinsukwini ezingu-20 kuya kwezingu-45 zokuhlolwa kwe-antibody-based.
3. I-Determine Combo yamanje ihlola kuphela ama-antigens e-HIV-1, hhayi ama-antigens e-HIV-2.
Awukwazi yini ukuhlukanisa phakathi kwe-HIV-1 ne-HIV-2 antibodies.
Konke lokhu kusho ukuthi labo abanesandulela-ngculazi-2 (okutholakala ngokuyinhloko eNtshonalanga Afrika) bangase babe nemiphumela ephansi kakhulu yemiphumela yokuhlolwa engavamile.
4. Ngenkathi i-Determine Combo ilungile, namanje akusiyo ukuhlolwa kokuphela kwesikhathi.
Ngisho noma umuntu evivinya ama-antigen anesandulela ngculaza kanye namagciwane omzimba we-HIV, ukuvivinya kwe-HIV-1 nucleic acid (NAT) okudingekayo kwenziwe. I-NAT ye-HIV-1 iyakwazi ukuthola i-RNA egazini namazinga aphezulu okuchithwa ngokungakapheli amasonto angu-1-2, ngemuva kokutheleleka.
5. I-Detemine Combo iyancipha ngesikhathi sokutheleleka okukhulu.
Naphezu kokuzwela kwe-antigen okungu-86% kuphela, inhlanganisela yokuhlolwa kwe-antibody / antigen kwandisa ukuzwela konke okungaphezu kuka-99%, lokhu ngokusho kwemibandela ebuyekeziwe ekhishwe i-CDC.
Noma kunjalo, akuzange kwenzeke nakanjani kubantu abane-infection yamuva (acute). Ngokusho kocwaningo oluvela eNyuvesi yaseCalifornia, eSan Francisco, i-Determine Combo yayikwazi ukukhomba isigamu sezifo ezithathelwanayo futhi ngokuvamile yenza kanjalo lapho umthamo wegciwane lesiguli ungaphezu kwama-500,000 amakhophi / mL.
Ngokuphambene, i- ARCHITECT inhlanganisela yokuhlola i-antigen / antibodybody test yenza okungcono kakhulu kokuhlolwa okungenzeka. Ngomqondo olinganisiwe phakathi kuka-99.1% nesimo esithile esingu-100%, ukuhlolwa kwakwazi ukukhomba cishe amaphesenti angama-90 we-infect acute.
Izwi elivela
Ukukhethwa kokuhlolwa kwegciwane lesandulela ngculazi kungaba umuntu oqobo, nabanye abantu abazonda izinaliti, abanye abafuna isivinini, kanti abanye besaba ukwesaba umphakathi. Ngenkathi i-Alere Determine Combo ne-Abbott ARCHITECT kokubili okukhethwa kukho okuhloswe kakhulu, okungafanele kukusize ekufuneni ezinye izinhlobo zokuhlolwa uma udinga ubumfihlo noma ukhetha ukuhlolwa kwe-saliva ngokuhlolwa kwegazi.
Uma ukhathazekile ngemfihlo, shayela umtholampilo wangakini bese ubuza ukuthi banikeza ukuhlolwa okuyimfihlo noma okungaziwa . Kunoma yikuphi,, qaphela ukuthi kunemithetho ekhona ukuqinisekisa ukuthi ulwazi mayelana nokuhlola kwakho nge-HIV alinakhululwa ngaphandle kwemvume yakho.
Ngaphambi kokwenza i-aphoyintimenti, cela umtholampilo mayelana nezinqubomgomo zabo zobumfihlo nokuthi bagcina kanjani imfihlo kusayithi . Ungaxhumana ne-hotline yakho yesimo se-HIV noma ushayele u-800-CDC-INFO (800-232-4636) ukuze ubone ukuthi kukhona yini amasayithi wokuhlola angaziwa endaweni yakho.
Into esemqoka ukuhlolwa nokuxhunyaniswa nokunakekelwa nokusekela okudingayo uma uthola ukuxilongwa okuhle.
> Imithombo:
> Ukuphathwa Kwezokudla Nezidakamizwa zase-US (FDA). "I-FDA ivumela ukuhlolwa kokuqala okusheshayo kokuthola ukuhlola ukuthi kune-anti-HIV-1 antigen ne-HIV-1/2 antibodies." I-Silver Spring, e-Maryland; ukushicilelwa okukhishwe ngo-Agasti 8, 2013.
> Branson, B .; Owen, uS .; I-Wesolowski, M .; et al. "Ukuvivinywa kwelabhulali yokuthola ukutheleleka nge-HIV: Izincomo ezibuyekeziwe." Amasevisi aseMelika okuLawula nokuvimbela izifo (CDC). I-Atlanta, Georgia; ikhishwe ngo-June 27, 2014.
> Pilcher, D .; Louie, B; Facente, S .; et al. "Ukusebenza kwe-Rapid Point-of-Care kanye nezivivinywa zeLebhubhu zeSandulela ngculazi eQinisekile futhi eqinisiwe eSan Francisco." I-PLOS | Eyodwa. NgoDisemba 12, 2013; I-DOI: 10.1371 / iphephandaba.pone.0080629.
> UMnyango wezeMpilo kanye nezinsizakalo zabasebenzi (DHHS). Ukuvivinya okuyimfihlo nokungaziwa. I-HIV.gov; ibuyekezwe ngo-Julayi 5, 2015